Journal
CANCER LETTERS
Volume 300, Issue 2, Pages 189-196Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.10.005
Keywords
Tubulin polymerization; JBIR-23; Malignant pleural me othelioma; Paclitaxel
Categories
Funding
- New Energy and Industrial Technology Development Organization (NEDO) of Japan [20380070]
- Ministry of Education Science Sports and Culture Japan
- Japan Society for the Promotion of Science (JSPS) of Japan
- JSPS [19 07627]
- Ministry of Education Culture Sports Science and Technology [H18-1-3-3-1]
- Grants-in-Aid for Scientific Research [22590375, 20380070] Funding Source: KAKEN
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with a poor prognosis Thus novel therapeutic agents need to be developed for treating it We recently reported the isolation of the novel anti-MPM compound designated as JBIR-23 from Strep tomyces sp AK-AB27 In this study JBIR-23 exerted its cytotoxic effect on MPM cells by promotion of tubulin polymerization and G(2)/M arrest which was followed by apoptosis induction via the caspase pathway through phosphorylation of p38 mitogen-activated protein kinase and c-jun N-terminal kinase Furthermore in vivo analysis demonstrated that JBIR-23 prevented tumor growth in tumor-bearing nude mice without evident side effects (C) 2010 Elsevier Ireland Ltd All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
